In this Nutritional Outlook analysis, Scott Mazza, co-founder of Vitality CBD, examines market data showing a decline in novelty CBD products in gas stations and convenience stores as the hemp sector matures. Mazza explains that consumers are increasingly distinguishing between wellness-focused CBD, best delivered through formats like gummies and topicals, and recreational cannabinoids such as delta-8 and THCA, which better fit convenience retail channels. He frames this shift as a positive correction driven by consumer education, science-backed applications, and demand for quality, testing, and credible producers, as published in Nutritional Outlook.

In this science-forward overview, Scott Mazza, co-founder and COO of Vitality CBD, examines the emerging research landscape around minor cannabinoids such as CBN, CBG, THCA, and THCV. The article synthesizes early findings on their distinct pharmacological profiles and potential applications, from sleep, pain, and inflammation to neuroprotection and skin health, while situating these compounds within the broader concept of the entourage effect. Mazza also addresses regulatory and quality challenges, arguing that evidence-based policy and rigorous research are essential to responsibly unlocking the therapeutic and nutritional potential of hemp’s lesser-known cannabinoids.

In this science-focused article, Scott Mazza, co-founder and COO of Vitality CBD, reviews emerging research on CBD’s potential role in supporting women during menopause. Drawing on clinical and observational studies, the piece examines how CBD may help address common symptoms such as sleep disruption, joint pain, anxiety, and mood changes, while emphasizing evidence around full-spectrum formulations and dosing. Mazza also highlights the importance of product quality, third-party testing, and cautious application as scientific understanding and regulatory oversight continue to evolve.

Scott Mazza examines the hemp industry’s leading regulatory priorities ahead of the upcoming Farm Bill, including classifying CBD as a conventional dietary supplement and food ingredient, easing testing bottlenecks, and adjusting federal THC limits for hemp. Drawing on current FDA, USDA, and industry positions, the article argues that existing regulatory frameworks can address safety and quality concerns without creating new, uncertain pathways. The piece frames these proposals as pragmatic, farmer-focused adjustments aimed at stabilizing the CBD market and providing clearer federal guidance.

In a commentary for Nutritional Outlook, Scott Mazza reviews 2023 as a year of regulatory stagnation but meaningful scientific and social progress for CBD, highlighting the delayed Farm Bill update, ongoing uncertainty around delta-8 THC, and FDA hesitation on CBD as a dietary supplement. He outlines key research milestones from the year, including emerging evidence on CBD’s role in opioid use disorder, dosage safety thresholds, hair loss, and other health conditions that continue to reshape the compound’s scientific credibility. Mazza concludes that declining social stigma and growing consumer adoption position CBD for further maturation in 2024, provided policymakers deliver clearer regulatory guidance and enforceable production standards.

In an article for Nutritional Outlook, Scott Mazza examines emerging research suggesting that topical hemp formulations rich in cannabinoids, including CBD, may support hair regrowth and could offer an alternative or complement to conventional treatments like finasteride and minoxidil. He highlights findings from a small clinical case series reporting significant hair regrowth without adverse effects, while emphasizing that the mechanism of action appears distinct from existing therapies. Mazza cautions that meaningful progress in CBD-based hair health depends on stronger industry-wide standards for purity, potency, and labeling to ensure consumer safety and scientific credibility.

In this industry analysis published by Nutritional Outlook, Scott Mazza, co-founder and COO of Vitality CBD, explains why delta-8 THC has become one of the most contested compounds in the hemp market, outlining its chemistry, production from hemp-derived CBD, and reported consumer effects. He examines the regulatory gray area created by the 2018 Farm Bill, contrasting federal legality with increasing state-level restrictions and FDA warnings tied to product safety and unsubstantiated claims. The article argues for clearer legislation, stronger quality standards, and expanded research to resolve uncertainty around delta-8 THC and protect both consumers and the broader hemp industry.

In this Nutritional Outlook article, Scott Mazza, co-founder and COO of Vitality CBD, argues that the 2023 Farm Bill must resolve ongoing regulatory ambiguity around CBD in foods, beverages, and dietary supplements. He outlines how the lack of clear FDA pathways has led to widespread issues with product purity, potency, labeling accuracy, and consumer safety, citing data on contamination and mislabeling across the market. Mazza calls for defined federal standards and enforcement, particularly around supplements and emerging cannabinoids like delta-8 THC, to protect consumers while providing long-term regulatory certainty for responsible producers.